Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Spruce Biosciences, a US-based developer of treatments for endocrine disorders, has floated in a $90m initial public offering representing an exit for pharmaceutical firm Novo. The company increased the number of shares in the offering from 5 million to 6 million and priced them at $15.00 each, in the middle of the $14 to $16…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.